Article Summary
Clinical trials show combination therapy boosts weight loss.
GLP-1s are already making headlines as they help growing numbers of patients lose weight and reclaim their health. Now physician-scientists are exploring even bigger benefits in studies combining GLP-1s with other weight loss medications targeting different locations in the brain for appetite control.
These combination therapies, using complimentary mechanisms to regulate appetite, show great promise to further revolutionize treatment for obesity and diabetes, said Endeavor Health endocrinologist and clinical researcher Liana Billings, MD, director of the clinical and genetics research program in diabetes and cardiometabolic disease.
How combining tirzepatide and eloralintide targets appetite
Dr. Billings is the principal investigator of a recent national trial combining Eli Lilly’s tirzepatide (brand name Zepbound) and a newer selective amylin receptor agonist, eloralintide (a drug that mimics the amylin hormone released by the pancreas after eating).
The study showed dramatic improvements in blood sugar control and weight loss, with significantly better results from the two drugs in combination, setting the stage for ongoing investigation and more treatment options in the future. These data were presented in September 2026 at the European Association for the Study of Diabetes in Milan, Italy.
Study patients on the eloralintide alone lost up to an average of 12.3% of their body weight and their hemoglobin A1c (HbA1c) lowered by up to a mean of 1.42%. Although this is a very positive clinically important result, those on varying combinations of doses of tirzepatide and eloralintide achieved up to 23.3% mean weight loss and up to 2.9% reduction in HbA1c during the 48-week study period, explained Dr. Billings.
How combination therapy compares to single medications and bariatric surgery
“This is more weight loss than we’ve seen with previous medications in people with Type 2 diabetes. With the combination therapy, 25% of the patients lost over 30% of their body weight,” said Dr. Billings, which moves the therapy into similar territory of results achieved with bariatric surgery.
The trial also addressed potential approaches to starting and combining medications with sequential doses as well as impacts on common side effects, including GI issues, she added. More data will be presented soon and will address other factors including lean or muscle and fat loss ratios.
While there has been widespread success with GLP-1s, there is still 10-15% of patients who don’t respond to the drugs even on the maximum dosage, said Dr. Billings.
“This research opens the door to personalizing our strategies for patients with obesity and Type 2 diabetes and to meet patients where they are,” said Dr. Billings, who is passionate about the promise of clinical trials and caring for patients with obesity and Type 2 diabetes.
What new metabolic clinical trials mean for patients at Endeavor Health
“Obesity is a chronic medical condition; these treatments are effective and life-changing,” emphasized Dr. Billings.
Endeavor Health currently offers more than 30 clinical trials for Type 1 and 2 diabetes, overweight/obesity and cardio-renal-metabolic disease. Eligible patients enrolled in studies receive VIP care with direct access to endocrinologists, research coordinators, nurses, dietitians, diabetes educators and advanced practice clinicians with extensive experience managing obesity and diabetes medications.
One of the biggest metabolic programs in the region, new trials are regularly available to patients who receive comprehensive care as study participants.
“We are so grateful to our patients who join these studies, and our team goes above and beyond to build individual relationships with each of them,” said Dr. Billings.
“We have an amazing community and have built a patient base who have been with us for decades. This program not only makes a positive impact on our individual study participants, but also benefits the greater scientific community and the rapidly expanding field of obesity treatment.”




